Abstract
Background: As many as 5% of the population in Central Europe suffer from insect venom allergy. The protective effect of conventional specific immunotherapy is quite convincing, as it is associated with a success rate up to 95%. We report our experience concerning ultra-rush dose titration in children and adolescents. Objective: The aim of this study was to examine the safety and tolerability of a shortened insect venom immunotherapy in children. Patients and methods: A modified version of the ultra-rush procedure was initiated for 38 bee venom and 54 wasp venom allergies in 90 patients (56 boys and 34 girls) aged 4 to 17 years. Consolidation therapy consisted of 100 μg boost injections administered after seven and 21 days while maintenance therapy was administered every four to six weeks. Results: All patients developed local reactions under VIT, of whom 20 had extensive reddening (>5 cm-20 cm), 15 patients developed significant wheals (5 cm-15 cm), and two patients with a bee venom allergy had systemic reactions which could be controlled well. Maintenance therapy was tolerated well by all patients. Conclusion: Ultra-rush titration is safe, tolerable and effective in children and adolescents, in addition to being associated with greater compliance and shorter hospital stays when compared to conventional therapy regimens. No serious side effects were registered. All patients could be discharged from the hospital at the latest after 48 hours.
Highlights
As many as 5% of the population in Central Europe suffer from insect venom allergy
The protective effect of conventional specific immunotherapy for insect venom allergy (VIT) is quite convincing, as it is associated with a success rate of 95%
Specific immunotherapy still is the sole causal therapy for Hymenoptera venom allergy; its safety and efficacy are accepted throughout the world
Summary
The protective effect of conventional specific immunotherapy for insect venom allergy (VIT) is quite convincing, as it is associated with a success rate of 95%. A number of treatment regimens have been published in the last few years for the preliminary phase of specific immunotherapy. These treatment regimens vary in terms of the duration of therapy, number of injections, and the administered dose of insect venom, as well as the frequency of systemic side effects during treatment [2,3,4,5]. The protective effect of conventional specific immunotherapy is quite convincing, as it is associated with a success rate up to 95%. We report our experience concerning ultra-rush dose titration in children and adolescents
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have